Erschienen in:
01.08.2007 | Adis Spotlight
Spotlight on Quetiapine in Bipolar Depression
verfasst von:
Gillian M. Keating, Dean M. Robinson
Erschienen in:
CNS Drugs
|
Ausgabe 8/2007
Einloggen, um Zugang zu erhalten
Abstract
Quetiapine (Seroquel®) is the only atypical antipsychotic approved in the US for use as monotherapy in both bipolar mania and depression, offering potential compliance advantages. Monotherapy with oral quetiapine 300 mg/day is effective in the treatment of patients with bipolar I or II depression. Rapid and sustained improvements in depressive and anxiety symptoms are seen with quetiapine, as well as improvements in health-related quality of life. Quetiapine is generally well tolerated in bipolar depression and is not associated with an increased risk of treatment-emergent mania. Thus, despite the current lack of data from active comparator trials, quetiapine monotherapy should be considered a first-line option for the acute treatment of bipolar depression.